Signaling between the placenta and the uterus involving the mitogen-regulated protein/proliferins

Biblio

Publication Type:

Journal Article

Source:

Endocrinology, Volume 140, Number 11, p.5239-49 (1999)

ISBN:

0013-7227 (Print)<br/>0013-7227 (Linking)

Accession Number:

10537154

Keywords:

*Signal Transduction, Amniotic Fluid/chemistry, Animals, Estradiol/blood/metabolism/pharmacology, Female, Gene Expression Regulation, Gestational Age, Glycoproteins/analysis/genetics/*metabolism, Glycosylation, Intercellular Signaling Peptides and Proteins, Mice, Mice, Inbred BALB C, Molecular Sequence Data, N-Acetylneuraminic Acid/metabolism, Placenta/chemistry/drug effects/*metabolism, Pregnancy, RNA, Messenger/analysis, Tissue Distribution, Uterus/growth & development/*metabolism

Abstract:

<p>The aim of this investigation was to examine signaling between the placenta and uterus during pregnancy. To do this, we determined the tissue messenger RNA and protein levels of members of a glycopeptide hormone family known to stimulate the proliferation of uterine cells and related these levels to the growth of the uterus during pregnancy in the mouse. This hormone family is known as mitogen-regulated protein (MRP); alternatively proliferin (PLF). Three mrp/plf genes, plf1, mrp3 and mrp4, are expressed by the placenta with different developmental profiles. The major increase of about 4-fold in DNA content of the uterus occurs between days 9 and 14 when MRP/PLFs are present in the placenta. By contrast, the gestational changes in estradiol-17beta levels in placental and uterine tissues and in circulation do not correlate with the period of uterine growth. The previously reported mitogenic activity of the MRP/PLFs and their gestational profiles suggest that one or more of these proteins stimulates uterine proliferation during gestation. Evidence is also presented that expression of MRP3 and/or PLF1, but not MRP4, is negatively regulated by feedback from the uterus. Our results are consistent with the hypothesis that MRP/PLFs stimulate uterine proliferation in vivo and that a uterine factor shuts off PLF1 and/or MRP3 synthesis in the latter half of gestation.</p>

Notes:

Fang, Y<br/>Lepont, P<br/>Fassett, J T<br/>Ford, S P<br/>Mubaidin, A<br/>Hamilton, R T<br/>Nilsen-Hamilton, M<br/>HD-29087/HD/NICHD NIH HHS/<br/>Endocrinology. 1999 Nov;140(11):5239-49.